Barrier Therapeutics Announces Azoline Dose Ranging Study in Tinea Versicolor Meets Primary and Secondary Endpoints
PRINCETON, NJ -- Mar 27, 2007 -- Barrier Therapeutics, Inc., a pharmaceutical company that develops and markets dermatology products, today announced positive results from its completed Phase 2b dose ranging study for its novel oral antifungal product candidate pramiconazole (previously known as Azoline). Pramiconazole met the primary endpoint of effectively treating tinea (pityriasis) versicolor, a common skin fungal infection characterized by a discolored, scaly, itchy rash primarily on the back, chest and upper arms. In addition, the secondary endpoints of complete cure, mycological cure and investigators' global assessment achieved statistical significance.
"We are extremely pleased with these excellent study results, which provide a solid medical and scientific foundation for continuing to advance the development of pramiconazole for fungal infections," commented Geert Cauwenbergh, Ph.D., Chief Executive Officer of Barrier Therapeutics. "With these data now in hand, we will begin to seek a development and commercialization partner for this important compound."
Study Design and Results
The randomized, double-blind, placebo-controlled dose ranging study enrolled 147 patients in six treatment groups. The study results demonstrated a positive linear dose response (p